BMAC – Biopharmaceutical Manufacturer's Advisory Council
An initiative by leading Biopharmaceutical companies in the world to establish Singapore as the country of choice for global biomedical sciences manufacturing.
Pfizer Inc. today announced the extension of the company’s highly automated Active Pharmaceutical Ingredient (API) manufacturing facility in Tuas Biomedical Park, Singapore. The official opening ceremony was graced by Singapore’s Deputy Prime Minister and Minister for Trade and Industry Mr. Gan Kim Yong.
The SGD$1 billion state-of-the-art facility extension spans 429,000 square feet and will produce various small molecule APIs for Pfizer’s oncology, pain, and antibiotic medicines to markets across the world. It has passed all necessary final performance qualification checks and begun commercial manufacturing of products.
Pfizer’s latest investment in Tuas Biomedical Park reinforces Singapore's standing as a leading biomedical sciences hub and also demonstrates how global biopharmaceutical companies can tap on our talent and capabilities to manufacture therapies for the world. We look forward to deepening our longstanding partnership with Pfizer to create meaningful jobs and economic opportunities for Singapore.
Pfizer is creating over 250 new highly skilled jobs with the site expansion, adding to the existing workforce of several hundred colleagues in the country. Pfizer has an established commercial and manufacturing presence in Singapore, and the expansion of the API plant demonstrates its continued commitment to operations in the country. Pfizer has more than 30 sites across six continents producing quality medicines for patients around the world.
With the facility expansion, Pfizer continues to grow its resilient and innovative global supply network. This expanded facility not only grows our overall manufacturing footprint but also strengthens our ability to manufacture breakthrough medicines that change patients' lives. We want to thank the Government of Singapore for making this site expansion a reality and look forward to continued collaboration to achieve our shared goals.
The facility, whose construction began in 2020, is designed to facilitate the lean movement of material, reduction in lead times, process turnarounds, and the continuation of best practice in Good Manufacturing Practices (GMP). In addition to the existing buildings, the facility has the capacity to add processing suites, dry-end suites, dispensaries, warehouse, and ancillary equipment as required in the future. Design priorities included integration of systems and technologies to help increase energy efficiency and enable effective energy demand management. Additionally, the facility has achieved a Green Mark gold certification1, a Singapore accreditation for environmental sustainability. These actions reflect Pfizer’s goal to achieve the voluntary Net-Zero standard by 2040 and contribute to a more sustainable future for years to come.
1 Green Mark is a green building rating system by the Building and Construction Authority (BCA) designed to evaluate a building’s environmental impact and performance. It provides a comprehensive framework for assessing the overall environmental performance of new and existing buildings to promote sustainable design, and best practices in construction and operations in buildings.
When he was a child, Mr Shaji Alias watched a family member struggle with asthma and saw the difference that one of GSK’s medicines made.
Every parent of a newborn knows the toll of sleepless nights, and Mr Lam Wain Sion is no exception. However, thanks to the 16 weeks
The Biologics Pharma Innovation Programme Singapore (BioPIPS) consortium has been expanded with the addition of global immunotherapy company, BioNTech. The company joins global pharmaceutical companies